{"id":"fuzuloparib-abiraterone-acetate-and-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Myelosuppression"}]},"_chembl":{"chemblId":"CHEMBL271227","moleculeType":"Small molecule","molecularWeight":"391.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fuzuloparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and inducing synthetic lethality in homologous recombination-deficient tumors. Abiraterone acetate blocks CYP17A1 to reduce intratumoral androgen synthesis, while prednisone provides glucocorticoid replacement and anti-inflammatory effects. Together, this triple combination targets both DNA repair deficiency and androgen signaling pathways in advanced prostate cancer.","oneSentence":"This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:34.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency"}]},"trialDetails":[{"nctId":"NCT06971211","phase":"PHASE2","title":"Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC","status":"RECRUITING","sponsor":"Jianbin Bi","startDate":"2024-11-27","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SHR3162"],"phase":"phase_3","status":"active","brandName":"Fuzuloparib , Abiraterone acetate and Prednisone","genericName":"Fuzuloparib , Abiraterone acetate and Prednisone","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer. Used for Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}